No single ticker was named. Weight-loss & pharma ETFs are one way for retail investors to get exposure. Not a recommendation.
GLP-1 market penetration surge to 30% by 2035
The thesis argued is that GLP-1 drug sales for diabetes and obesity are projected to surge from $150 billion to $190 billion by 2035, driven by a massive increase in market penetration from 6% to 30% of obese Americans.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.